Our study has provided a novel STAT3 inhibitor with significant anti-tumor activities in NSCLC and suggests that combination of STAT3 inhibitor such as W2014-S with gefitinib could serve as a promising strategy to overcome EGFR-TKIs acquired resistance in NSCLC patients.
No takes yet. Share an insight, caveat, or question.
Zheng et al. (2020) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: